Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.

Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Antinuclear antibodies during procainamide treatment and drug acetylation.

Cryoglobulins in the procainamide-induced lupus syndrome.

Drug-induced antinuclear antibodies and lupus syndromes.

Acetylator phenotype in diabetic neuropathy.

Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.

Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermittent porphyria.

The effect of food on procainamide absorption.

Determination of the acetylator phenotype in a Northern Nigerian population.

Significance of the acetylation phenotype and the therapeutic effect of procainamide.

The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.

Acetylator phenotype and the antihypertensive response to hydralazine.

Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide.

Determination of the acetylator phenotype using matrix isoniazid.

Antinuclear antibodies in patients on lithium carbonate.

Antinuclear antibodies in children.

The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial.

Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in the sera of patients with Felty's syndrome.

IgG, IgM, and IgA antinuclear antibodies in discoid and systemic lupus erythematosus patients.

In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies.

Procainamide, acetylprocainamide, and drug-induced lupus erythematosus.

Clinical features and antinuclear antibodies profile among adults with systemic lupus erythematosus and lupus nephritis: a cross-sectional study.

Comparison of the complement-fixing activity of antinuclear antibodies in lupus nephritis, mixed connective tissue disease, and scleroderma.

Absorption of serum antinuclear antibodies.

Suggest Documents

Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Antinuclear antibodies during procainamide treatment and drug acetylation.

Cryoglobulins in the procainamide-induced lupus syndrome.

Drug-induced antinuclear antibodies and lupus syndromes.

Acetylator phenotype in diabetic neuropathy.

Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.

Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermittent porphyria.

The effect of food on procainamide absorption.

Determination of the acetylator phenotype in a Northern Nigerian population.

Significance of the acetylation phenotype and the therapeutic effect of procainamide.

The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.

Acetylator phenotype and the antihypertensive response to hydralazine.

Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide.

Determination of the acetylator phenotype using matrix isoniazid.

Antinuclear antibodies in patients on lithium carbonate.

Antinuclear antibodies in children.

The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial.

Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in the sera of patients with Felty's syndrome.

IgG, IgM, and IgA antinuclear antibodies in discoid and systemic lupus erythematosus patients.

In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies.

Procainamide, acetylprocainamide, and drug-induced lupus erythematosus.

Clinical features and antinuclear antibodies profile among adults with systemic lupus erythematosus and lupus nephritis: a cross-sectional study.

Comparison of the complement-fixing activity of antinuclear antibodies in lupus nephritis, mixed connective tissue disease, and scleroderma.

Absorption of serum antinuclear antibodies.

Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.

Recommend Documents

Follow Us